MiMedx Group, Inc. (MDXG) Stock

MiMedx Group, Inc. (MDXG) is a Healthcare stock trading at $4.29 (as of 2026-08-20), with a market capitalization of $625.31M and a trailing P/E of 100.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MiMedx Group, Inc. develops and distributes placental tissue allografts used in healthcare. Its product line includes EpiFix for chronic wound care, AmnioFix and related amnion/chorion or umbilical cord allografts for surgical recovery and wound healing, and AMNIOBURN for burn treatment.

Understand MiMedx Group, Inc.: how it makes money

MiMedx Group develops and distributes placental tissue allografts, processing human placental tissue using its patented PURION process to produce products such as EpiFix, and it generates revenue by selling these allografts to healthcare customers.

MiMedx starts with proprietary PURION processing that supports high gross profitability, and then its profit depends on turning commercialization activity, such as MiMedx Connect adoption and physician training, into enough net sales to offset operating costs, since operating margin is negative.

Revenue by segment (latest quarter)
Hosp$0.1B
PrivateOffice$0.0B
Other$0.0B

Business quality (Weak): Product-level economics look strong (high gross margin), but the latest quarter shows a large operating loss, so investors must focus on whether sales traction can cover operating expenses.

Valuation: At 18× earnings, MDXG trades 43% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • High gross margin in the latest quarter (gross_margin_pct = 70.6%): This suggests the company’s processed placental tissue product economics are favorable at the gross-profit level.
  • Commercial execution is measurable through MiMedx Connect: The provided operating metrics show 1,000 Customers Using MiMedx Connect and 25% MiMedx Connect Active Customer Adoption.

Bear case

  • Operating profitability is currently negative (operating_margin_pct = -27.2%): Even with high gross margin, operating costs are large enough to produce an operating loss.
  • Some product line contribution appears limited in the provided breakdown: Net Sales from Section 351 Products are shown as 0.0 in the provided segment candidates.
Valuation — source: SEC EDGAR (first-party)
Price$4.29
Market Cap$625.31M
P/E Ratio100.3
EV / EBITDA21.6
Price / Book2.89
Price / Sales1.76
DCF Value (model)$7.89
DCF Upside vs Price83.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$418.63M
Net Margin11.6%
Revenue Growth (YoY)-34.7%
EPS Growth (YoY)-242.9%
Financial Health — source: SEC EDGAR
Altman Z-Score6.85 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E100.3
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector364.2%
vs Industry205.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderEssex Woodlands Management, Inc. ($111.37M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOJoseph H. Capper
Employees837
CountryUS
IPO Date2008-02-12

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Beta Bionics, Inc. (BBNX)
  • SS Innovations International, Inc. (SSII)
  • OrthoPediatrics Corp. (KIDS)
  • AngioDynamics, Inc. (ANGO)
  • Delcath Systems, Inc. (DCTH)
  • Cerus Corporation (CERS)
  • Tactile Systems Technology, Inc. (TCMD)
  • NeuroPace, Inc. (NPCE)
MDXG earnings history · MDXG institutional & insider holders · MDXG KPIs & operating metrics · MDXG financials · MDXG investor presentations & press releases · MDXG SEC filings · MDXG peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.